FDA approves drug to treat rare hemoglobinuria.
Thompson
Cheryl A
CA
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001803:Blood Transfusion; D017277:Drug Approval; D004348:Drug Labeling; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D017261:Glycosylphosphatidylinositols; D006457:Hemoglobinuria, Paroxysmal / Q000188:drug therapy*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D008589:Meningococcal Infections / Q000150:complications / Q000209:etiology; D009894:Opportunistic Infections / Q000150:complications / Q000209:etiology; D012308:Risk Management; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017261:Glycosylphosphatidylinositols; C481642:eculizumab